Alliance Shift: Private Biotechs See Up-Front Cash Boost In 2012
This article was originally published in Start Up
Executive Summary
Biopharma alliance volume has dropped over the past five years, but in 2012, privately held out-licensers averaged better up-fronts than their publicly traded counterparts, according to Elsevier’s Strategic Transactions.